A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
Experimental Gerontology Feb 16, 2018
Kraig E, et al. - Rapamycin (RAPA) is an FDA-approved immunosuppressive drug used as a clinical therapy to prevent solid organ allograft rejection. This study was designed to determine the safety as well as tolerability of RAPA in older human subjects. Findings suggested safety of short-term RAPA treatment in older persons who were otherwise healthy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
